Cargando…
Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer
Tyrosine kinases (TKs) play a significant role in cancerogenesis and cancer cell function. Initial developments in this field go back to the early 80s, but the success story really started with the selective BCR-ABL inhibitor, imatinib. Owing to the cancer-driving role of BCR-ABL in chronic myeloid...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567050/ https://www.ncbi.nlm.nih.gov/pubmed/26401097 http://dx.doi.org/10.4137/BMI.S22432 |
_version_ | 1782389765931270144 |
---|---|
author | Na, Il-Kang le Coutre, Philipp |
author_facet | Na, Il-Kang le Coutre, Philipp |
author_sort | Na, Il-Kang |
collection | PubMed |
description | Tyrosine kinases (TKs) play a significant role in cancerogenesis and cancer cell function. Initial developments in this field go back to the early 80s, but the success story really started with the selective BCR-ABL inhibitor, imatinib. Owing to the cancer-driving role of BCR-ABL in chronic myeloid leukemia (CML), excellent response rates lead to fast FDA approval in both the first and second treatments of CML patients. Since then, numerous TKs were identified. TK inhibitors have been developed accordingly, and technology to test for ideal drug–target interactions has profoundly improved. By now, medical oncologists and hematologists struggle to have a pool of potential TK inhibitors, where the most efficient one could be picked out to treat a specific cancer patient, which might also help overcome the occurring resistance mechanisms against TK inhibitors. Whether disease eradication can be achieved via single or sequential TK inhibitor treatment(s) needs to be tested in the present and in the future. |
format | Online Article Text |
id | pubmed-4567050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-45670502015-09-23 Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer Na, Il-Kang le Coutre, Philipp Biomark Insights Commentary Tyrosine kinases (TKs) play a significant role in cancerogenesis and cancer cell function. Initial developments in this field go back to the early 80s, but the success story really started with the selective BCR-ABL inhibitor, imatinib. Owing to the cancer-driving role of BCR-ABL in chronic myeloid leukemia (CML), excellent response rates lead to fast FDA approval in both the first and second treatments of CML patients. Since then, numerous TKs were identified. TK inhibitors have been developed accordingly, and technology to test for ideal drug–target interactions has profoundly improved. By now, medical oncologists and hematologists struggle to have a pool of potential TK inhibitors, where the most efficient one could be picked out to treat a specific cancer patient, which might also help overcome the occurring resistance mechanisms against TK inhibitors. Whether disease eradication can be achieved via single or sequential TK inhibitor treatment(s) needs to be tested in the present and in the future. Libertas Academica 2015-09-10 /pmc/articles/PMC4567050/ /pubmed/26401097 http://dx.doi.org/10.4137/BMI.S22432 Text en © 2015 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License. |
spellingShingle | Commentary Na, Il-Kang le Coutre, Philipp Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer |
title | Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer |
title_full | Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer |
title_fullStr | Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer |
title_full_unstemmed | Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer |
title_short | Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer |
title_sort | emerging role of tyrosine kinases as drugable targets in cancer |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567050/ https://www.ncbi.nlm.nih.gov/pubmed/26401097 http://dx.doi.org/10.4137/BMI.S22432 |
work_keys_str_mv | AT nailkang emergingroleoftyrosinekinasesasdrugabletargetsincancer AT lecoutrephilipp emergingroleoftyrosinekinasesasdrugabletargetsincancer |